0  0%
Previous Close 14.19
Open 14.17
Price To book 0.00
Market Cap 1.54B
Shares 109,201,000
Volume 886,018
Short Ratio 16.11
Av. Daily Volume 1,384,710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 study completion due 2018.
Closed Triple
Filing announced November 21, 2016. PDUFA estimate September 21, 2017.
Chronic obstructive pulmonary disease (COPD)

Latest News

  1. Sarissa Asks Innoviva Directors To Explain Continued Director Over-Compensation Despite Promises To Cut Costs
  2. Innoviva, Inc. – Value Analysis (NASDAQ:INVA) : April 24, 2017
  3. Sarissa Takes Innoviva to Court Over Busted Agreement
  4. Innoviva, Inc. breached its 50 day moving average in a Bearish Manner : INVA-US : April 21, 2017
  5. Innoviva to Report First Quarter Financial Results on April 27 at 5:00 p.m. EDT
  6. Overwhelming Majority Of Non-GSK Shareholders Support Sarissa Capital And Not Innoviva Board And Management
  7. Sarissa Lawsuit Likely After Innoviva Claims Win Over Dissidents
  8. Here's Why Innoviva Inc. Lost 10% Today
  9. Innoviva Says It Fends Off Sarissa Dissidents
  10. Innoviva Announces Preliminary Results of Annual Meeting
  11. Innoviva director vote drama hands last-minute loss to Sarissa
  12. Innoviva prevails in proxy fight against activist Sarissa-source
  13. Activist Sarissa says Innoviva backed out of proxy settlement deal
  14. Innoviva Reneges On Accepted Deal With Sarissa Capital
  15. Innoviva Urges Shareholders to Vote “FOR” All of Innoviva’s Value-Creating Directors On the WHITE Proxy Card TODAY
  16. Innoviva Issues Statement on Upcoming Annual Meeting of Stockholders
  17. Sarissa Capital States: Innoviva Already Appears To Renege On Cost Cuts; Innoviva Thinks Its Bad Corporate Governance Is Not A Problem
  18. Sarissa Urges Shareholders To See Through Innoviva's Last Minute Flip-Flop On Cost Cuts; Notes Conspicuous Absence Of Promises To Fix Bad Corporate Governance
  19. Innoviva Board Recommends Shareholders Vote “FOR” All of Innoviva’s Qualified Directors on the WHITE Proxy Card
  20. Innoviva to review costs, executive pay following Sarissa pressure